Author

Цзя-Хорнг Као

18 апреля 2023 г.
Доказательства преимуществ раннего начала лечения хронического гепатита В
Summary Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current international CHB guidelines recommend antiviral treatment only in subsets of patients with clear evidence of liver damage. This contrasts […]

Читать далее
16 февраля 2022 г.
Глобальные изменения в распространенности вируса гепатита С и каскаде оказания медицинской помощи в период с 2015 по 2020 год: модельное исследование
Summary Background Since the release of the first global hepatitis elimination targets in 2016, and until the COVID-19 pandemic started in early 2020, many countries and territories were making progress toward hepatitis C virus (HCV) elimination. This study aims to evaluate HCV burden in 2020, and forecast HCV burden by 2030 given current trends. Methods This analysis […]

Читать далее